Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnology startup companies. Based in Cambridge, Massachusetts, the firm partners with life science entrepreneurs to translate scientific breakthroughs into medicines.
31% of their portfolio is in Biotech & Life Sciences. Deal activity increased 75% year-over-year (7 deals in the last 12 months). Average disclosed round size is $54.2M (across 181 rounds with reported amounts).
Portfolio
166
Fund Size
$400M
Top Stage
Series A
Last 12 Mo
8
Team
Akshay Vaishnaw, MD, PhD
Venture Partner
Bob Copeland, PhD
Venture Partner
Bruce Booth, DPhil
Partner
Charlie Albright, PhD
Venture Partner
David Grayzel, MD
Partner
Jason Rhodes
Partner
Jean-François Formela, MD
Partner
Jeff Albers, JD, MBA
Venture Partner
Linda C. Bain
Venture Partner
Phillip Samayoa, PhD
Venture Partner; Chief Operating Officer, Ethyreal Bio
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| VVima | Series A | $100M | Mar 2026 |
 Kinaset Therapeutics | Series B | $103M | Jan 2026 |
| KKinaset | Series B | $103M | Jan 2026 |
| VVima Therapeutics, Inc. | Unknown | $40M | Jan 2026 |
 TRIANA Biomedicines | Series B | $120M | Dec 2025 |
 Lifordi Immunotherapeutics | Unknown | — | Nov 2025 |
 AAVantgarde Bio | Series B | — | Nov 2025 |
| KKailera | Series B | $600M | Oct 2025 |
 Vima Therapeutics | Series A | $60M | May 2025 |
 Exowatt | Series A | $50M | Apr 2025 |
| VVima Therapeutics, Inc. | Series A | $60M | Jan 2025 |
 Triveni Bio | Series B | $115M | Oct 2024 |
 Kailera Therapeutics | Series A | — | Oct 2024 |
 Pheon Therapeutics | Series B | $120M | May 2024 |
 Diagonal Therapeutics | Series A | $128M | Apr 2024 |
 Accent Therapeutics | Series C | $75M | Jan 2024 |
 Comanche Biopharma | Series B | $75M | Jan 2024 |
 Remix Therapeutics | Series C | $60M | Jan 2024 |
 Vigil Neuroscience | Series A | $50M | Jan 2024 |
| SSionna | Series C | $182M | Jan 2024 |
| NnChroma | Unknown | $75M | Jan 2024 |
| Triveni Bio | Series A | $92M | Oct 2023 |
| AAiolos Bio | Series A | $245M | Oct 2023 |
 Ai Build | Series A | $8.5M | Oct 2023 |
| AAi Build Limited | Series A | $8.5M | Oct 2023 |
Top Co-Investors
Last updated: 9 September 2026